Enhanced apoptosis induction in BRAF-mutant melanoma cells in combination with dabrafenib/trametinib, DNA damage, suppression of DNA repair genes, downregulation of HR and NHEJ DNA repair, MGMT expression as a sensitivity marker, increased tumor growth inhibition of A375 xenografts (regression of 70%). The gene discussed is BRAF; the disease is melanoma.